Skip to main content

Table 4 Meta-analysis of prognostic roles of mTOR/p-mTOR expression in patients with ESCC

From: Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis

Endpoint event N No. samples Heterogeneity (I2, p) Model HR with 95 % CI P value Publication bias Conclusion
Total PE NE Begg (p) Egger (p)
Overall survival 6 713 381 332 I2 = 0.0 %, p = 0.493 Fixed 2.036 (1.582–2.620) <0.001 1.0 0.663 Significant
Disease-free survival 3 330 197 133 I2 = 0.0 %, p = 0.970 Fixed 2.390 (1.637–3.490) <0.001 1.0 0.941 Significant
Cancer-specific survival 2 308 145 163 I2 = 0.0 %, p = 0.853 Fixed 1.620 (1.179–2.229) 0.003 1.0 NI Significant
  1. CI confidence interval, ESCC esophageal squamous cell carcinoma, HR hazard ratio, mTOR Mammalian Target of Rapamycin, N reference count, NE negative expression, NI no information, PE positive expression, p-mTOR Phosphorylated Mammalian Target of Rapamycin